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Abstract 
Background: Patients with severe aortic stenosis (AS) and heart failure have poor prognosis, and their 
outcomes may be suboptimal even after transcatheter (TAVR) and surgical aortic valve replacement (SAVR).  
Methods: This is an analysis of the nationwide FinnValve registry which included patients who underwent 
primary TAVR or SAVR with a bioprothesis for AS. We evaluated the outcome of patients with acute heart 
failure (AHF) within 60 days prior to TAVR or SAVR. 
Results: The prevalence of recent AHF was 11.4% (484/4241 patients) in the SAVR cohort and 11.3% 
(210/1855 patients) in the TAVR cohort. In the SAVR cohort, AHF was associated with lower 30-day survival 
(91.3% vs. 97.0%; adjusted OR 1.801, 95%CI 1.125-2.882) and 5-year survival (64.0% vs. 81.2%; adjusted HR 
1.482, 95%CI 1.207-1.821). SAVR patients with AHF had higher risk of major bleeding, need of mechanical 
circulatory support, acute kidney injury, prolonged hospital stay and composite end-point (30-day 
mortality, stroke and/or acute kidney injury). Patients with AHF had a trend toward lower 30-day survival 
(crudes rates, 95.2% vs. 97.9%; adjusted OR 2.028 95%CI 0.908-4.529) as well as significantly lower 5-year 
survival (crude rates, 45.3% vs. 58.5%; adjusted HR 1.530, 95%CI 1.185-1.976) also after TAVR. AHF 
increased the risk of acute kidney injury, prolonged hospital stay and composite end-point after TAVR. 
Conclusions: Recent AHF is associated with increased risk of mortality and morbidity after SAVR and TAVR. 
These findings suggest that AS patients should be referred for invasive treatment before the development 
of clinically evident heart failure.  
 
Clinical trial registration: ClinicalTrials.gov Identifier: NCT03385915 
Key-words: Transcatheter aortic valve replacement; TAVR; TAVI; Surgical aortic valve replacement; AVR; 
Aortic valve stenosis; Acute heart failure. 
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Acute heart failure (AHF) may complicate the course of aortic stenosis (AS) (3,4) and it is the main cause of 
death in these patients (5-7). Historical data showed that when symptoms of heart failure develop, 
patient’s prognosis is dismal (7). A recent multicenter study by Nagao et al. (8) confirmed the negative 
prognostic impact of AHF secondary to AS and that the increased risk of all-cause death persisted after 
aortic valve replacement. In this study we evaluated the early and late outcomes of patients with recent 
AHF after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) from a nationwide registry.  
 
Patients and Methods 
Study data 
The FinnValve registry is a nationwide registry (ClinicalTrials.gov Identifier: NCT03385915), which 
retrospectively collected data from consecutive patients who underwent TAVR or SAVR with a 
bioprosthesis for severe AS with or without coronary revascularization at all five Finnish university hospitals 
(Helsinki, Kuopio, Oulu, Tampere and Turku) from January 2008 to October 2017. This study was approved 
by the Institutional Review Board of the participating centers. The inclusion criteria for entering this registry 
were: 1) AS with or without aortic valve regurgitation; 2) patients aged >18 years; and 3) primary TAVR or 
SAVR with a bioprosthesis with or without concomitant coronary revascularization. The exclusion criteria of 
this study were: 1) any prior TAVR or surgical intervention on the aortic valve; 2) concomitant major cardiac 
procedure on the ascending aorta and/or other heart valves or structures; 3) transcatheter or surgical 
procedure for isolated aortic valve regurgitation; and/or 4) acute endocarditis. For the purpose of the 
present analysis, only patients with data on the timing of hospitalization for treatment of AHF were 
included in this study. Patients with an episode of AHF >60 days before index procedure were excluded 
from the study, because such a delay to invasive treatment might suggest less severe episodes of heart 
failure or chronic heart failure with less severe prognosis (8). Patients who underwent transapical TAVR 
were excluded from this analysis because its invasiveness and suboptimal results favored the current use of 
less invasive peripheral vascular approaches.  
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Data was collected retrospectively into an electronic case report form with pre-specified baseline- and 
operative covariates and outcomes by cardiologists, cardiac surgeons and research nurses. Data underwent 
robust checking of its completeness and quality by the local investigators. Further data checking was 
performed by repeating selected data collection into a control Excel datasheet. Longitudinal data included 
only all-cause mortality occurred during the follow-up period. Data on mortality was retrieved from the 
national Population Register Center (Väestörekisteri) by linkage of patients’ social security numbers. The 
last date of follow-up was December 31
st
, 2018. This registry is a highly reliable registry collecting data from 
the death certificates issued by physicians and these should be promptly delivered for further checking and 
collection of the information in to this national registry.  Follow-up was considered complete for all 
patients, but for two patients (0.003%) not residing in Finland at the time of the index procedure and 
whose follow-up was truncated at hospital discharge. 
 
Definition Criteria of Baseline Risk Factors 
Baseline variables were defined according to the EuroSCORE II criteria (9). The operative risk of these 
patients was stratified according to the EuroSCORE II (9) and STS (10) risk scores. Severe frailty was defined 
according to the Geriatric Status Scale (GSS) and herein is defined as GSS grades 2-3 (11). Coronary artery 
disease was defined as any stenosis ≥50% of the main coronary branches. Recent AHF was defined as any 
new-onset or worsening of symptoms and signs of heart failure requiring hospital admission and rapid 
escalation of therapy within 60 days from TAVR or SAVR. Critical preoperative state was defined as 
ventricular tachycardia or fibrillation or aborted sudden death, preoperative cardiac massage, preoperative 
ventilation before anesthetic room, preoperative inotropes or intra-aortic balloon pump insertion (IABP) 
and/or preoperative acute renal failure (9). Critical preoperative state at admission for TAVR or SAVR 
procedure was considered as a condition comparable to AHF.  
 
Outcome Measures 
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The primary outcomes were 30-day and 5-year survival. The secondary outcomes were stroke, use of IABP 
and/or extracorporeal membrane oxygenation (ECMO), blood transfusion, transfusion of >4 units of red 
blood cells (RBC) and/or resternotomy for bleeding (12) and/or transfusion of >4 units of RBC and/or 
resternotomy or any reoperation for peripheral bleeding, major and life threatening VARC-2 bleeding (13), 
moderate to severe paravalvular regurgitation, implantation of permanent pace-maker, acute kidney injury 
and postoperative length of stay in the hospital where the procedure was performed and a composite end-
point including 30-day death, stroke and/or KDIGO acute kidney injury stage 3. The length of stay in the 
intensive care unit was not considered in this analysis because of inter-institutional differences in the 
organizational program of postoperative care of patients undergoing TAVR. Stroke was defined as any focal 
or global neurological deficit lasting 24 hours or longer with a new brain infarct or hemorrhage detected at 
neuroimaging, or a neurological deficit resulting in death. Valve Academic Research Consortium-2 (VARC-2) 
consensus document major bleeding was defined as bleeding either associated with a drop in the 
hemoglobin level of at least 3.0 g/dL or requiring transfusion of two or three units of RBC, or causing 
hospitalization or permanent injury, or requiring surgery (13). VARC-2 life threatening bleeding was defined 
as any bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery or 
overt source of bleeding with drop in hemoglobin ≥5.0 g/dL or transfusion of more than three units of RBC 
or causing death (13). Acute kidney injury was defined according to the KDIGO classification criteria (14), 
i.e. an increase in serum creatinine ≥1.5 times the baseline level or serum creatinine increase ≥26.5 μmol/l 
and/or de novo renal replacement therapy during the hospital stay. Stage 3 acute kidney injury was defined 
as any increase in serum creatinine ≥3.0 times the baseline level or serum creatinine increase ≥353.65 
μmol/l during the hospital stay and/or de novo renal replacement therapy during the hospital stay. 
 
Statistical Analysis  
Statistical analysis was performed using SAS statistical package, version 9.2 (SAS Institute Inc, Cary, NC), 
SPSS v. 25.0 statistical software (IBM Corporation, New York, USA) and Stata v. 15.0 (SAS Institute Inc., Cary, 
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NC, USA). The normal distribution of continuous variables was assessed with the Shapiro-Wilk test which 
showed that none of the continuous variables was normally distributed. The Mann-Whitney U-test, Fisher’s 
exact test, Chi-square test and linear-by-linear association tests were used for univariate analysis in the 
overall population. Logistic and Cox regression analyses without stepwise selection were employed for risk 
adjusted analysis of binary outcomes. Ordinal and linear regression methods were employed to adjust the 
risk for rank-ordered and continuous outcomes. Regression models were adjusted for the following 
covariates: following covariates: age, gender, anemia (<1.2 g/dL in women, <1.3 g/dL in men), estimated 
glomerular filtration rate, diabetes, stroke, pulmonary disease, extracardiac arteriopathy, left ventricular 
ejection fraction 50% or less, porcelain aorta, atrial fibrillation, frailty GSS grades 2-3, active malignancy, 
recent myocardial infarction, coronary artery disease, prior percutaneous coronary intervention and prior 
cardiac surgery. The Kaplan-Meier method was used to estimate late survival in the study cohorts. 
Propensity score matching analysis was used to compare the outcomes after TAVR and SAVR in patients 
with AHF and the employed methods are described in the Supplementary material. All tests were two-sided 
and p<0.05 was set for statistical significance.  
 
Results 
Characteristics and Outcomes of the Overall Registry 
The FinnValve registry includes data from 6463 patients who underwent primary TAVR and SAVR with a 
bioprothesis for severe AS. The Institutional volumes of TAVR and SAVR ranged from 263 to 254 patients 
and from 532 to 1403 patients, respectively. Thirty-day mortality in patients without prior AHF was 2.7%, 
whereas it was 8.2% in patients with AHF within 30 days before the procedure, 5.2% in patients with AHF 
31-60 days before the procedure, 2.1% in patients with AHF 61-90 days before procedure and 2.8% (36 
patients) in patients with AHF episode more than 90 days before the procedure (p<0.0001). Since patients 
with AHF episode within 60 days from the procedure had a markedly increased risk of early death, the 
outcomes of these patients were compared with those of patients without history of AHF. After excluding 
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patients who underwent transapical TAVR and those without data on the timing of hospitalization for AHF, 
6 096 patients were available for the present analysis (Fig. 1).  
 
Characteristics and Outcomes of the Study Cohorts  
The prevalence of recent AHF was 11.4% (484/4241 patients) in the SAVR cohort and 11.3% (210/1855 
patients) in the TAVR cohort (Fig. 1). The proportion of patients with recent AHF undergoing SAVR 
decreased significantly along the study period (Linear-by-linear association test, p=0.002), whereas no 
significant changes were observed among patients undergoing TAVR (Linear-by-linear association p=0.258) 
(Suppl. Fig. 1). The baseline characteristics of patients in the TAVR and SAVR cohorts are summarized in 
Table 1. Patients with recent AHF had markedly increased operative risk compared to patients with no AHF 
both in the TAVR (STS score 8.1±6.8 vs. 4.0±2.2%, p<0.0001) and the SAVR cohort (STS score 7.0±5.8 vs. 
2.6±3.2%, p<0.0001) (Tab. 1). The mean follow-up of this series was 4.3±2.7 years (median, 3.9 years; 
range, 0-11.7 years) and its completeness was 99.9%.  
In the overall series, recent AHF was associated with significantly lower 30-day survival (crude rates, 92.5% 
vs. 97.3%; adjusted for treatment method and multiple covariates OR 1.579, 95%CI 1.212-2.708) and 5-year 
survival (crude rates, 64.0% vs. 81.2%; adjusted for treatment method and multiple covariates HR 1.523, 
95%CI 1.300-1.786). 
Among 4241 patients who underwent SAVR, recent AHF was associated with significantly lower 30-day 
survival (crude rates, 91.3% vs. 97.0%; adjusted for multiple covariates OR 1.801, 95%CI 1.125-2.882) and 5-
year survival (crude rates, 64.0% vs. 81.2%; adjusted for multiple covariates HR 1.482, 95%CI 1.207-1.821). 
In the SAVR cohort, when adjusted for multiple covariates, patients with recent AHF had higher risk of 
major bleeding, need of mechanical circulatory support, acute kidney injury, prolonged hospital stay as well 
as of composite end-point compared to patients without AHF (Tab. 2). 
Among 1855 patients who underwent TAVR, recent AHF showed a trend toward lower 30-day survival 
(crudes rates, 95.2% vs. 97.9%; adjusted for multiple covariates OR 2.028 95%CI 0.908-4.529) as well as 
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lower 5-year survival (crude rates, 45.3% vs. 58.5%; adjusted for multiple covariates HR 1.530, 95%CI 1.185-
1.976). In the TAVR cohort, when adjusted for multiple covariates, patients with recent AHF had higher risk 
of postoperative acute kidney injury, prolonged hospital stay as well as of composite end-point compared 
to patients without AHF (Tab. 2). 
Propensity score matching resulted in 130 pairs with similar baseline characteristics (Suppl. tab. 1). Among 
these matched pairs, 30-day survival (94.6% vs. 96.1%, p=0.527, Suppl. tab. 2) were similar in the study 
cohorts. After a mean follow-up of 2.9±2.5 years, 1-, 3-, and 5-year survival in the TAVR cohort were 86.8%, 
71.4% and 49.5% and in the SAVR cohort were 82.1%, 70.0% and 63.0%, respectively (restricted mean 
survival time ratio, 1.001, 95%CI 0.886-1.132, p=0.947, Suppl. fig. 2). 
 
Comment 
This study provides evidence of the poor early and late prognosis of AS patients with recent AHF 
undergoing aortic valve replacement. The present findings suggest that release of high afterload by TAVR or 
SAVR should be performed before the development of irreversible pathological changes and clinically 
evident heart failure. Recent studies documented a benefit of early operative treatment in patients with 
peak aortic jet velocity of 5.0 m/s or greater and with reduced left ventricular ejection fraction (7,8).  
Recent AHF was an independent predictor of poor early and intermediate survival after SAVR. A trend 
toward poorer 30-day survival was observed also after TAVR and adjusted analysis confirmed the negative 
prognostic impact of AHF on 5-year survival after TAVR. It is worth noting that the observed 30-day 
mortality after TAVR was markedly lower than predicted by the EuroSCORE II and STS risk scores, while the 
observed 30-day mortality was similar to the expected rates in the SAVR cohort. Similarly, recent AHF was 
associated with increased risk of several early adverse events after SAVR, but not after TAVR.  
In the present study, a significant number of patients with recent AHF and increased STS score were treated 
surgically. This may be related to several factors such as the delay between referral and TAVR treatment 
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during the early study period, which was significantly shortened during the last few years. Furthermore, 
most of these patients were at intermediate risk and only recently the evidence on the safety and efficacy 
of TAVR in these patients has driven a shift toward it. This resulted in a decrease of the proportion of 
patients with recent AHF undergoing SAVR in this series (Likelihood ratio test, p=0.016; Suppl. Fig. 1).  
A recent study showed in patients with asymptomatic AS that 2 years after recommendation for SAVR 
(93.2% underwent surgery) survival was 92.5% whilst it was 83.9% when watchful waiting was 
recommended (47.2% underwent surgery) (p=0.044) (15). In 2016 Généreux et al. (16) pooled the available 
evidence on this topic and showed that patients with severe asymptomatic AS have 3.5-fold higher rate of 
all-cause death with a watchful waiting strategy compared with aortic valve replacement. The present 
study further documented the magnitude of the adverse events in patients who develop clinically evident 
heart failure and highlight the importance of early referral to invasive treatment for severe AS.  
This data does not allow an analysis of the impact of the timing of treatment when AHF develops. However, 
we speculate that AS patients with AHF may benefit from an early release of the high afterload to the same 
extent of urgent balloon aortic valvuloplasty in the setting of AS-related cardiogenic shock (17). In view of 
the similar risk of adverse events after balloon aortic valvuloplasty and TAVR (18), patients with AHF 
secondary to severe AS may be considered for primary TAVR. Although, this may require changes of the 
diagnostic and treatment pathway, current evidence suggests that urgent/emergency TAVR may pay off 
with excellent early and intermediate survival (19). However, the present study was not able to document 
the validity of TAVR over SAVR in this setting because of the limited number of patients included in this 
analysis. In propensity score matched pairs of patients, SAVR was associated with increased risk of major 
bleeding, acute kidney injury and prolonged hospital stay compared to TAVR and after a mean follow-up of 
2.9 years, 3-year survival was similar in the study cohorts. Lower survival was observed after TAVR at 5 
years, but the limited number of patients at risk prevented conclusive results on the efficacy of these 
treatment methods on the long run. 
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In this study, hospital stay was shorter in patients with no recent AHF than in patients with recent AHF 
(SAVR, mean 8.0 vs. 10.7 days, p<0.0001; TAVR, mean 5.0 vs. 6.5 days, p<0.0001). Furthermore, among 
propensity score matched pairs, TAVR was associated with significantly shorter hospital stay, which is likely 
related to benefits of using this minimally invasive treatment method (Suppl. tab. 2). Hospital stay in 
patients with recent AHF significantly declined from 2009 to 2017 after TAVR (mean, 16.7 to 4.4 days, 
ordinal regression p<0.0001), but not after SAVR (mean, 12.6 to 10.8 days, ordinal regression p=0.214) 
(data not shown).  
 
Limitations 
The retrospective nature is the main limitation of this study. Second, the definition of AHF is based on 
history of recent hospitalization for its treatment, but neither the severity of AHF nor information on its 
treatment were captured in this registry. Third, the limited number of patients does not allow a 
comparative analysis of patients without coronary artery disease undergoing SAVR or TAVR. Finally, the 
relatively small sample size of this study as well as the rather short follow-up (mean, 2.9 years) are 
potential biases of this study and limited the validity of comparative analysis of TAVR versus SAVR. On the 
other hand, this dataset represents a 10-year nationwide experience with these treatment methods, and 
the unselected nature of this series and reliability of data on survival are the strengths of this analysis. 
 
Conclusions 
Recent AHF is associated with increased morbidity and mortality after SAVR and TAVR. These findings 
suggest that TAVR and SAVR should be performed before the early and late outcome is jeopardized by the 
development of irreversible pathological changes and clinically evident heart failure. Larger studies are 
needed to assess the potential benefits of TAVR over SAVR in these high risk patients.   
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Figure Legends 
Figure 1. Study flowchart.   
Figure 2. Survival in patients with and without recent acute heart failure after transcatheter (TAVR) and 
surgical aortic valve replacement (SAVR). 
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Table 1. Characteristics of patients with and without recent acute heart failure undergoing transcatheter 
and surgical aortic valve replacement.  
AHF, acute heat failure; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; eGFR, glomerular 
filtration estimated according to the MDRD equation; LVEF, left ventricular ejection fraction; Frailty, GSS grades 2-3; SPAP, systolic 
pulmonary artery pressure; PCI, percutaneous coronary intervention. 
  
 SAVR  TAVR  
Characteristics No AHF 
3757 pts 
AHF 
484 pts 
p-value No AHF 
1645 pts 
AHF 
210 pts 
p-value 
Age, years 75.0±6.4 75.2±7.1 0.375 81.6±6.5 80.7±6.6 0.039 
Female 1785 (47.5) 203 (41.9) 0.021 945 (57.4) 111 (52.9) 0.206 
Anemia 903 (24.0) 255 (52.7) <0.0001 711 (43.2) 137 (65.2) <0.0001 
eGFR, ml/min/1.73m
2
 77±21 70±24 <0.0001 66±22 60±25 <0.0001 
Diabetes 960 (25.6) 165 (34.1) <0.0001 440 (26.7) 67 (31.9) 0.114 
Stroke 241 (6.4) 48 (9.9) 0.004 184 (11.2) 22 (10.5) 0.758 
Pulmonary disease 525 (14.0) 103 (21.3) <0.0001 351 (21.3) 39 (18.6) 0.354 
Extracardiac arteriopathy 446 (11.9) 78 (16.1) 0.008 267 (16.2) 41 (19.5) 0.227 
LVEF ≤50% 559 (14.9) 301 (62.3) <0.0001 350 (21.3) 119 (56.9) <0.0001 
Porcelain aorta 12 (0.3) 2 (0.4) 0.486 79 (4.8) 9 (4.3) 0.740 
Atrial fibrillation 766 (20.4) 163 (33.7) 0.000 680 (41.3) 116 (55.2) <0.0001 
Frailty 95 (2.5) 11 (2.3) 0.734 218 (13.3) 43 (20.5) 0.005 
Active malignancy 46 (1.2) 12 (2.5) 0.025 69 (4.2) 6 (2.9) 0.354 
SPAP   <0.0001   <0.0001 
31-55 mmHg 1269 (33.8) 222 (45.9)  651 (39.6) 111 (52.9)  
>55 mmHg 175 (4.7) 112 (23.1)  189 (11.5) 39 (18.6)  
Missing data 93 (2.5) 11 (2.3)  276 (16.8) 15 (7.1)  
Coronary artery disease 1647 (43.8) 272 (56.2) <0.0001 446 (27.1) 74 (35.2) 0.014 
Prior cardiac surgery 85 (2.3) 10 (2.1) 0.784 293 (17.8) 30 (14.3) 0.205 
Recent myocardial infarction 133 (3.5) 161 (33.3) <0.0001 24 (1.5) 15 (7.1) <0.0001 
Urgency of the procedure   <0.0001   <0.0001 
Urgent 194 (5.2) 317 (65.5)  26 (1.6) 101 (48.1)  
Emergency 11 (0.3) 47 (9.6)  0 (0) 5 (2.4)  
Recent balloon valvuloplasty 5 (0.1) 6 (1.2) 0.001 32 (1.9) 16 (7.6) <0.0001 
Planned concomitant 
revascularization 
1534 (40.8) 252 (52.1) <0.0001 9 (0.5) 1 (0.5) 0.895 
Critical preoperative state 0 96 (19.8) <0.0001 0 28 (13.3) <0.0001 
EuroSCORE II, % 3.1±2.7 12.1± 1.1 <0.0001 5.9±5.2 13.5±13.6 <0.0001 
STS Score, % 2.6±3.2 7.0± 5.8 <0.0001 4.0±2.2 8.1±6.8 <0.0001 
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Table 2. Outcomes after transcatheter and surgical aortic valve replacement in patients with and without recent acute heart failure. 
 SAVR   TAVR   
Outcomes No AHF 
3757 pts 
AHF 
484 pts 
Univariate 
analysis 
P-value 
Multivariate analysis 
Risk estimates, 
95%CI 
No AHF 
1645 pts 
AHF 
210 pts 
Univariate 
analysis 
P-value 
Multivariate analysis 
Risk estimates, 
95%CI 
Mortality, %   <0.0001    <0.0001  
30-day 3.0 8.7  1.801, 1.125-2.882 2.1 4.8  2.028, 0.908-4.529 
1-year 5.9 16.8   7.7 16.7   
3-year 10.8 28.4   22.8 37.9   
5-year 18.8 36.0   41.5 54.7   
Stroke 139 (3.7) 22 (4.5) 0.359 0.840, 0.484-1.456 36 (2.2) 8 (3.8) 0.146 1.849, 0.781-4.377 
ECMO or IABP 49 (1.3) 27 (5.6) <0.0001 2.213, 1.199-4.084 1 (0.1) 0 (0.0) 0.887 - 
RBC transfused, units 2.7±3.6 5.0±5.1 <0.0001 1.223, 0.826-1.620 0.5±1.4 0.7±1.6 0.020 0.169, -0.050-0.387 
Transfusion of >4 RBC units and/or 
resternotomy for bleeding 
773 (20.9) 225 (46.9) <0.0001 2.152, 1.685-2.749 46 (2.8) 10 (4.8) 0.122 1.865, 0.852-4.086 
Transfusion of >4 RBC units and/or any 
operation for bleeding 
775 (20.9) 225 (46.9) <0.0001 2.148, 1.682-2.743 69 (4.3) 15 (7.2) 0.056 1.801, 0.950-3.416 
VARC-2 bleeding grades   <0.0001 0.453, 0.213-0.694   0.617 0.382, 0.056-0.709 
Major bleeding 1402 (37.4) 133 (27.7)   402 (24.5) 56 (26.8)   
Life-threatening bleeding 2204 (58.7) 333 (69.2)   101 (6.2) 15 (7.2)   
Resternotomy for bleeding 289 (7.7) 50 (10.3) 0.044 1.217, 0.828-1.787 8 (0.5) 3 (1.4) 0.119 4.191, 0.932-18.838 
KDIGO acute kidney injury stages   <0.0001 0.866, 0.360-1.372   <0.0001 0.597, 0.346-0.848 
1 459 (12.3) 99 (21.0)   63 (3.9) 18 (9.1)   
2 98 (2.6) 29 (6.1)   18 (1.1) 3 (1.5)   
3 90 (2.4) 30 (6.4)   7 (0.4) 5 (2.5)   
Permanent pacemaker 147 (3.9) 16 (3.3) 0.513 0.856, 0.469-1.562 157 (9.5) 16 (7.6) 0.366 0.808, 0.458-1.423 
Moderate or severe paravalvular 
regurgitation 
22 (0.6) 5 (1.0) 0.244 2.555, 0.763-8.548 60 (3.6) 7 (3.3) 0.818 1.073, 0.460-2.507 
Hospital stay, days 8.0±5.8 10.7±9.3 <0.0001 2.085, 1.391-2.779 5.0±4.2 6.5±6.0 <0.0001 1.447, 0.769-2.126 
Composite end-point
a
 283 (7.5) 81 (16.7) <0.0001 1.617, 1.157-2.261 69 (4.2) 20 (9.5) 0.001 2.266, 1.272-4.037 
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; AHF, acute heat failure; KDIGO, Kidney Disease: Improving Global Outcomes; ECMO, extracorporeal 
membranous oxygenation; IABP, intra-aortic balloon pump; RBC, red blood cell units; VARC, Valve Academic Research Consortium; a, 30-day death, stroke and/or KDIGO acute kidney injury 
stage 3. Risk estimates are odds ratios and coefficients with their 95% confidence interval (CI). 
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